Tiragolumab Clinical Trials
9 recruitingDrug
Phase 27Phase 14Phase 31
Showing 1–9 of 9 trials
Recruiting
Phase 3
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Cancer
Hoffmann-La Roche100 enrolled57 locationsNCT05862285
Recruiting
Phase 1Phase 2
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Cancer
Alliance Foundation Trials, LLC.148 enrolled21 locationsNCT04486352
Recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Metastatic Colorectal Cancer
Hoffmann-La Roche542 enrolled74 locationsNCT04929223
Recruiting
Phase 1Phase 2
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Advanced Liver Cancers
Hoffmann-La Roche518 enrolled33 locationsNCT04524871
Recruiting
Phase 2
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
Squamous Cell CarcinomaOral Cavity Squamous Cell Carcinoma
M.D. Anderson Cancer Center29 enrolled1 locationNCT05681039
Recruiting
Phase 1Phase 2
Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma
M.D. Anderson Cancer Center10 enrolled1 locationNCT05394337
Recruiting
Phase 2
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
Head and Neck CancerCancerCarcinoma+1 more
Alain Algazi55 enrolled1 locationNCT03708224
Recruiting
Phase 2
Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients
Solid Tumor, Adult
Omico96 enrolled13 locationsNCT06003621
Recruiting
Phase 2
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
Metastatic Breast Cancer
The Netherlands Cancer Institute60 enrolled1 locationNCT06342037